Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Seattle Genetics Diversifies Beyond ADCs With Cascadian Acquisition

Jan 31 2018

• By Joseph Haas

Businessman draws a statistical trend line

Related Content

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

May 05 2017

Oncothyreon reports another tecemotide failure

Aug 20 2014

Seattle Genetics Looking To Improve, Replace Standards Of Care

Jan 30 2018

Stimuvax failure dents Merck Serono but freshens Oncothyreon

Dec 20 2012

Related Companies

Seagen Inc.

Cascadian Therapeutics, Inc.

Astellas Pharma, Inc.

Genmab A/S

Genentech, Inc.

Merck KGaA

Additional Topics

M & A Commercial Deals Cancer BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window